Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Early viral kinetics do not predict treatment outcome with sofosbuvir+ribavirin for 12 or 24 weeks in HCV genotype 2/3 patients in the valence trial

Renate Heyne,H Hinrichsen,D Huppe,Michael Peter Manns,Jorgen Soberg Petersen, J Schulzezurwiesch,Ulrich Spengler,Dieter Haussinger, T Berg,D Brainard,William T Symonds,John G Mchutchison, Linda C Gallo,T Warger,Nicole Forestier,Stefan Zeuzem,Martin Rossle,Christoph Eisenbach,S Christensen,Norbert H Gruner

Zeitschrift Fur Gastroenterologie（2014）

Cited 0|Views25
No score
Abstract
Background: Sofosbuvir (SOF) + ribavirin (RBV) for 12 or 24 weeks led to high SVR rates in genotype 2 or 3 HCV-infected patients, respectively, in the Phase 3 VALENCE study. We analyzed viral kinetics to determine the relationship to SVR12.
More
Translated text
Key words
hcv genotype,early viral kinetics
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined